Acasti Pharma rises after HC Wainwright starts with "buy"

Grace Therapeutics

26/06/2019 12:56

** Canada-based drug developer's U.S.-listed shares  ACST.O 
rise 18.10% to $1.24 premarket 
    ** HC Wainwright starts coverage on ACST with a "buy"
rating, citing potential of co's krill oil based therapy CaPre
for hypertriglyceridemia; sets PT of $6 
    ** Based on survey results conducted by the brokerage,
Wainwright believes there is potential for co's drug to
differentiate itself from other therapies that use omega-3 fatty
acids, such as Amarin Corp's  AMRN.O  Vascepa 
    ** If approved, CaPre would represent the only prescription
omega-3 offering triglyceride reduction benefits, without
raising LDL-cholesterol levels
    ** Both of the brokerages covering the stock rate it "buy"
or higher
    ** Up to Tuesday's close, stock had risen 26.22% YTD

 (Reporting by Manas Mishra in Bengaluru)
 ((Reuters Messaging:
manas.mishra.thomsonreuters.com@reuters.net))